[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360606-105":59,"doc-detail-360606-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","site-specific-neoepitope-induction-by-rna-editing-reprograms-tumor-immunogenicity","Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity","","Site-specific neoepitope induction by RNA editing is presented as a strategy to remodel tumor immunogenicity where conventional mutation-derived neoantigen supply is limited. The work introduces REISN to generate defined neoantigen-like epitopes by targeting predeﬁned TCR-contact residues in MHC-I presented peptides from shared cancer/testis and oncofetal antigens, including murine P1A and human AFP. Using an MS2 coat protein (MCP)-ADAR-based A-to-I editing system and lipid nanoparticle circular RNA vaccination, the study demonstrates activation of REISN-specific naïve T cells and suppression of tumor growth in immunocompetent BALB/c mice, supporting clinical translation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/site-specific-neoepitope-induction-by-rna-editing-reprograms-tumor-immunogenicity/360606/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/site-specific-neoepitope-induction-by-rna-editing-reprograms-tumor-immunogenicity/360606.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What strategy does the study introduce to improve tumor immunogenicity?","Question",{"text":113,"@type":114},"It introduces REISN (RNA Editing-Induced Site-specific Neoantigen) to remodel tumor immunogenicity by generating defined neoantigen-like epitopes from preselected targets.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is site-specific RNA editing implemented in this work?",{"text":118,"@type":114},"An MS2 coat protein (MCP)-ADAR-based A-to-I RNA editing system is used to selectively modify TCR-contact residues in MHC-I-presented peptides.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence is shown for immune activation and antitumor effects?",{"text":122,"@type":114},"Site-directed RNA editing produces REISN-modified epitopes that activate REISN-specific naïve T cells, and lipid nanoparticle-formulated P1A-REISN circular RNA vaccination elicits potent CD8+ responses and suppresses tumor growth in BALB/c mice.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360606,1790597955,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Original Research PUBLISHED 09 June 2026  \nDOI 10.3389/fimmu.2026.1839930  \nOPEN ACCESS  \nEDITED BY  \nJose A. Garcia-Sanz,  \nSpanish National Research Council (CSIC), Spain  \nREVIEWED BY  \nZongde Zhang,  \nSouthwest Medical University, China Jingjing Pu,  \nShanghai Jiao Tong University, China  \n*CORRESPONDENCE  \nXiaoling Wang  \n[wangxiaoling@gzhmu.edu.cn](wangxiaoling@gzhmu.edu.cn)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 26 March 2026  \nREVISED 01 May 2026  \nACCEPTED 25 May 2026  \nPUBLISHED 09 June 2026  \nCITATION  \nLiu S, Dong C, Chen L, Yan J, Luo X, Huang H, Qiu Z, Gan X, Yang J, Zhu J, Xiong C, Huang L, Wang L, Yang Z, Meng Z, Yi S, Chen Y, Zuo C, Leng Q and Wang X (2026) Site-speciﬁc neoepitope induction by RNA editing reprograms tumor immunogenicity. Front. Immunol. 17:1839930 .  \ndoi: 10.3389/fimmu.2026.1839930  \nCOPYRIGHT  \n© 2026 Liu, Dong, Chen, Yan, Luo, Huang, Qiu, Gan, Yang, Zhu, Xiong, Huang, Wang, Yang, Meng, Yi, Chen, Zuo, Leng and Wang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nSite-speciﬁc neoepitope induction by RNA editing reprograms tumor immunogenicity  \nShangyuan Liu 1†, Chunxiu Dong 2†, Lin Chen 1†, Jiahong Yan 1, Xiaoshan Luo 1, HaiChao Huang 1, Zonghao Qiu 2, Xuhong Gan 1, Jiali Yang 2, Jiafeng Zhu 2, Chengjie Xiong 1, Lihong Huang 1, Linlin Wang 1, Zhengning Yang 1, Zhongxuan Meng 1, Senrong Yi 1, Yuxin Chen 1, Chijian Zuo 2, Qibin Leng 3 and Xiaoling Wang 1*  \n1Guangzhou Medical University-Guangzhou Institutes of Biomedicine and Health (GMU-GIBH) Joint School of Life Sciences, Guangdong Provincial Key Laboratory of Protein Modiﬁcation and Disease, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, Guangdong, China, 2Suzhou CureMed Biopharma Technology Co., Ltd., Suzhou, China, 3State Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Afﬁliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China  \nIntroduction: Neoantigens derived from somatic mutations exhibit high immunogenicity and speciﬁcity. However, their stochastic nature necessitates personalized vaccine design, and cancers with low tumor mutational burden often have insufﬁcient neoantigen availability, limiting their clinical applicability. Here, we introduce RNA Editing-Induced Site-speciﬁc Neoantigen (REISN) as a strategy to remodel tumor immunogenicity by targeting predeﬁned epitopes in widely expressed cancer/testis and embryonic antigens, including murine P1A and human AFP.  \nMethods: We leveraged an MS2 coat protein (MCP)-ADAR-based A-to-I RNA editing system to selectively modify T cell receptor (TCR)-contact residues in major histocompatibility complex class I (MHC-I)-presented peptides derived from P1A and AFP. We further evaluated the immunogenicity and antitumor efﬁcacy of lipid nanoparticle-formulated P1A-REISN circular RNA vaccination in immunocompetent BALB/c mice bearing tumors with P1A-REISN induction. Results: Site-directed RNA editing generated REISN-modiﬁed epitopes capable of activating REISN-speciﬁc naïve T cells. Vaccination with lipid nanoparticleformulated P1A-REISN circular RNA elicited potent antigen-speciﬁc CD8+ T cell responses and suppressed tumor growth in immunocompetent BALB/c mice. Discussion: These ﬁndings provide proof-of-concept that site-directed RNA editing can be used to reprogram tumor immunogenicity by generating deﬁned neoantigen-like epitopes from shared tumor-associated antigens. This strategy may expand neoanti","cbCail9f9Zokbtpv","https://ap.wps.com/l/cbCail9f9Zokbtpv","pdf",3202854,"English","# Introduction\n# Methods\n# Results\n# Discussion","[{\"question\":\"What strategy does the study introduce to improve tumor immunogenicity?\",\"answer\":\"It introduces REISN (RNA Editing-Induced Site-specific Neoantigen) to remodel tumor immunogenicity by generating defined neoantigen-like epitopes from preselected targets.\"},{\"question\":\"How is site-specific RNA editing implemented in this work?\",\"answer\":\"An MS2 coat protein (MCP)-ADAR-based A-to-I RNA editing system is used to selectively modify TCR-contact residues in MHC-I-presented peptides.\"},{\"question\":\"What evidence is shown for immune activation and antitumor effects?\",\"answer\":\"Site-directed RNA editing produces REISN-modified epitopes that activate REISN-specific naïve T cells, and lipid nanoparticle-formulated P1A-REISN circular RNA vaccination elicits potent CD8+ responses and suppresses tumor growth in BALB/c mice.\"}]","Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity | PDF",1790140690,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73be7a164202c73b799b3312d888ce07.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/582e8c61fcb6b34a9f3d47438441d862.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b775d1cef27638acb792d4d3fdc691b.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a19855fb9508d1dcd8d4ab815db2cc4a.webp",980,1385]